Skip to main content
Bloomberg Law

How Life Sciences Firms Can Reduce DOJ Enforcement Risks

May 6, 2021
Authors
Jaime L.M. JonesJack W. Pirozzolo

The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.

View Article

Contacts

Jones, Jaime L.M.
パートナー
Pirozzolo, Jack W.
パートナー

Related Blogs

Capabilities

Suggested News & Insights

Ninth Circuit Rejects $8.5M Award Of Attorneys’ Fees to FCA WhistleblowerApril 14, 2026
Original Source
DOJ Announces First FCA Settlement Resolving Title VII Discrimination AllegationsApril 13, 2026
Original Source
White House and DOJ Announce Sweeping New Anti-Fraud InitiativesApril 10, 2026
Sidley Updates
Ninth Circuit Opens Door to FCA Liability for Alleged 340B OverchargesMarch 19, 2026
Original Source
Fourth Circuit Highlights Tougher Path to Dismissal of FCA Cases Post-SuperValuMarch 18, 2026
Original Source
Fifth Circuit Panel Produces Three Opinions Wrestling with Application of First to File BarMarch 13, 2026
Original Source